Current assets increased 32.6%
Current assets changed +32.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Current assets changed +32.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Working capital changed +53.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating margin changed +776 basis points from the comparable as-filed period.
Free-cash-flow proxy changed +46.5% from the comparable as-filed period.
Operating cash flow changed +46.6% from the comparable as-filed period.
Revenue changed +29.9% from the comparable as-filed period.
Trade receivables changed +37.3% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Gross profit changed +30.4% from the comparable as-filed period.
Total assets changed +25.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating income changed +118.3% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Current liabilities changed +22.3% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Working capital / assets changed +397 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Capital expenditure changed +47.1% from the comparable as-filed period.
Receivables / revenue changed +358 basis points from the comparable as-filed period.
Research & development changed +19.8% from the comparable as-filed period.
Net income changed +196.7% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
SBC / revenue changed -177 basis points from the comparable as-filed period.
Cash & equivalents changed +12.7% from the comparable as-filed period.
Gross margin changed +33 basis points from the comparable as-filed period.
Inventory changed +19.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed +18.8% from the comparable as-filed period.
Current ratio changed +8.4% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
R&D / revenue changed -170 basis points from the comparable as-filed period.
Operating cash-flow margin changed +165 basis points from the comparable as-filed period.
Inventory / revenue changed -94 basis points from the comparable as-filed period.
Free-cash-flow margin changed +144 basis points from the comparable as-filed period.
Capex / revenue changed +20 basis points from the comparable as-filed period.
Free-cash-flow proxy changed +60.2% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes.
Operating cash flow changed +54.7% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes.
Operating margin changed +1057 basis points from the comparable as-filed period.
Revenue changed +30.5% from the comparable as-filed period.
Gross margin changed -191 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
SBC / revenue changed -483 basis points from the comparable as-filed period.
Gross profit changed +27.3% from the comparable as-filed period.
Inventory changed +37.9% from the comparable as-filed period.
Operating income changed +121.6% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Net income changed +301.2% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Cash & equivalents changed -15.5% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Research & development changed +17.2% from the comparable as-filed period.
Capital expenditure changed +19.0% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes.
Capex / revenue changed -17 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Inventory / revenue changed +58 basis points from the comparable as-filed period.
Stock-based compensation changed +0.5% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.